相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Histone deacetylase inhibitors in hematological malignancies and solid tumors
Pusoon Chun
ARCHIVES OF PHARMACAL RESEARCH (2015)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors
Jin-Soo Kim et al.
CANCER LETTERS (2015)
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia
Franck Morschhauser et al.
INVESTIGATIONAL NEW DRUGS (2015)
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation
David J. Straus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis
Rene Scholtysik et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2015)
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Dieter Hoelzer et al.
BLOOD (2014)
A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Michinori Ogura et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
PAX5 overexpression is not enough to reestablish the mature B-cell phenotype in classical Hodgkin lymphoma
L. Dimitrova et al.
LEUKEMIA (2014)
Ensembl 2014
Paul Flicek et al.
NUCLEIC ACIDS RESEARCH (2014)
Epigenetic mechanisms of importance for drug treatment
Maxim Ivanov et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma
Lihua E. Budde et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor
Marian Iwamoto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors
Caterina Ierano et al.
CELL CYCLE (2013)
Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
Yasuhiro Oki et al.
CLINICAL CANCER RESEARCH (2013)
Next-generation-sequencing-based risk stratification and identification of new genes involved in structural and sequence variations in near haploid lymphoblastic leukemia
Cai Chen et al.
GENES CHROMOSOMES & CANCER (2013)
Histone acetylation and DNA demethylation of T cells result in an anaplastic large cell lymphoma-like phenotype
Maria Joosten et al.
HAEMATOLOGICA (2013)
STRING v9.1: protein-protein interaction networks, with increased coverage and integration
Andrea Franceschini et al.
NUCLEIC ACIDS RESEARCH (2013)
The Sensitivity of Diffuse Large B-Cell Lymphoma Cell Lines to Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated by BCL-2 Family Protein Activity
Ryan C. Thompson et al.
PLOS ONE (2013)
RNA-Guided Human Genome Engineering via Cas9
Prashant Mali et al.
SCIENCE (2013)
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong et al.
SCIENCE (2013)
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
C. Visco et al.
LEUKEMIA (2012)
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing
Julia Richter et al.
NATURE GENETICS (2012)
Novel therapeutic agents for B-cell lymphoma: developing rational combinations
Craig B. Reeder et al.
BLOOD (2011)
Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Mark Kirschbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Dasatinib, imatinib and staurosporine capture compounds - Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS)
Jenny J. Fischer et al.
JOURNAL OF PROTEOMICS (2011)
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2011)
Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors
Ju-Hee Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
SAHA Capture Compound - A novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders
Jenny J. Fischer et al.
PROTEOMICS (2011)
Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor
William McLaren et al.
BIOINFORMATICS (2010)
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma
Jose A. Richter-Larrea et al.
BLOOD (2010)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
Takashi Watanabe et al.
CANCER SCIENCE (2010)
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Omar Khan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2009)
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells
Warren Fiskus et al.
BLOOD (2008)
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Jennifer S. Carew et al.
CANCER LETTERS (2008)
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma
Valeria R. Fantin et al.
CANCER RESEARCH (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification
Juergen Cox et al.
NATURE BIOTECHNOLOGY (2008)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Guillermo Garcia-Manero et al.
BLOOD (2008)
Capture compound mass spectrometry:: A technology for the investigation of small molecule protein interactions
Hubert Koester et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2007)
Activity-based probes for proteomic profiling of histone deacetylase complexes
Cleo M. Salisbury et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Molecular diagnosis of Burkitt's lymphoma
Sandeep S. Dave et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling
Michael Hummel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
B cell antigen receptor signaling 101
JM Dal Porto et al.
MOLECULAR IMMUNOLOGY (2004)
Essential role of Src-family protein tyrosine kinases in NF-κB activation during B cell development
K Saijo et al.
NATURE IMMUNOLOGY (2003)
Cytoscape: A software environment for integrated models of biomolecular interaction networks
P Shannon et al.
GENOME RESEARCH (2003)
Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain
SJ Schreiner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
分享论文
